ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -65.27 KRW | 58.91% |
| 2022 | -158.85 KRW | -53.76% |
| 2021 | -103.31 KRW | 50.69% |
| 2020 | -209.53 KRW | -1333.17% |
| 2019 | -14.62 KRW | 90.33% |
| 2018 | -151.13 KRW | 8.85% |
| 2017 | -165.81 KRW | -100.4% |
| 2016 | -82.74 KRW | -389.4% |
| 2015 | 28.59 KRW | -3.35% |
| 2014 | 29.58 KRW | -64.8% |
| 2013 | 84.03 KRW | -58.59% |
| 2012 | 202.92 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -55.00 KRW | -113.9% |
| 2024 Q1 | 395.68 KRW | 279.86% |
| 2023 FY | - KRW | 58.91% |
| 2023 Q3 | -147.53 KRW | -131.82% |
| 2023 Q4 | -219.99 KRW | -49.12% |
| 2023 Q2 | 463.58 KRW | 399.01% |
| 2023 Q1 | -155.04 KRW | -264.71% |
| 2022 FY | - KRW | -53.76% |
| 2022 Q4 | -42.51 KRW | 64.44% |
| 2022 Q3 | -119.56 KRW | -8.69% |
| 2022 Q2 | -110.00 KRW | -196.29% |
| 2022 Q1 | 114.24 KRW | -43.82% |
| 2021 Q3 | -162.80 KRW | -21.34% |
| 2021 Q4 | 203.34 KRW | 224.9% |
| 2021 Q1 | 16.57 KRW | 103.35% |
| 2021 FY | - KRW | 50.69% |
| 2021 Q2 | -134.17 KRW | -909.72% |
| 2020 Q2 | 47.93 KRW | -8.32% |
| 2020 Q4 | -494.71 KRW | -700.52% |
| 2020 Q3 | 82.38 KRW | 71.88% |
| 2020 FY | - KRW | -1333.17% |
| 2020 Q1 | 52.28 KRW | -45.61% |
| 2019 Q3 | -157.78 KRW | -576.01% |
| 2019 Q1 | -68.20 KRW | -222.76% |
| 2019 FY | - KRW | 90.33% |
| 2019 Q4 | 96.12 KRW | 160.92% |
| 2019 Q2 | -23.34 KRW | 65.78% |
| 2018 FY | - KRW | 8.85% |
| 2018 Q4 | -21.13 KRW | 67.07% |
| 2018 Q3 | -64.17 KRW | -166.27% |
| 2018 Q2 | -24.10 KRW | 42.39% |
| 2018 Q1 | -41.83 KRW | 67.86% |
| 2017 Q2 | -33.26 KRW | -253.13% |
| 2017 FY | - KRW | -100.4% |
| 2017 Q4 | -130.14 KRW | -438.44% |
| 2017 Q1 | 21.72 KRW | 177.6% |
| 2017 Q3 | -24.17 KRW | 27.33% |
| 2016 Q2 | -27.82 KRW | -181.58% |
| 2016 Q4 | -27.99 KRW | -7.12% |
| 2016 FY | - KRW | -389.4% |
| 2016 Q1 | -9.88 KRW | -151.22% |
| 2016 Q3 | -26.13 KRW | 6.07% |
| 2015 Q2 | -14.87 KRW | -190.18% |
| 2015 Q1 | 16.49 KRW | 3333.33% |
| 2015 FY | - KRW | -3.35% |
| 2015 Q4 | 19.29 KRW | 406.3% |
| 2015 Q3 | 3.81 KRW | 125.62% |
| 2014 Q4 | -0.51 KRW | -113.11% |
| 2014 FY | - KRW | -64.8% |
| 2014 Q1 | 9.55 KRW | -1.14% |
| 2014 Q2 | 43.04 KRW | 350.68% |
| 2014 Q3 | 3.89 KRW | -90.96% |
| 2013 FY | - KRW | -58.59% |
| 2013 Q1 | 35.76 KRW | 0.0% |
| 2013 Q2 | 35.76 KRW | 0.0% |
| 2013 Q4 | 9.66 KRW | 0.0% |
| 2013 Q3 | 9.66 KRW | -72.99% |
| 2012 FY | - KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| HLB Co., Ltd. | -1559.61 KRW | 95.815% |
| iNtRON Biotechnology, Inc. | -292.11 KRW | 77.656% |
| BINEX Co., Ltd. | 151.04 KRW | 143.214% |
| Bioneer Corporation | -410.19 KRW | 84.088% |
| Anterogen.Co.,Ltd. | -291.93 KRW | 77.642% |
| MEDIPOST Co., Ltd. | 287.00 KRW | 122.742% |
| CrystalGenomics, Inc. | -661.00 KRW | 90.126% |
| Helixmith Co., Ltd | -1543.76 KRW | 95.772% |
| Chabiotech Co.,Ltd. | -149.80 KRW | 56.429% |
| Medy-Tox Inc. | 1456.65 KRW | 104.481% |
| Peptron, Inc. | -773.61 KRW | 91.563% |
| Amicogen, Inc. | -583.58 KRW | 88.816% |
| Genexine, Inc. | -1652.14 KRW | 96.049% |
| HLB Therapeutics Co.,Ltd. | -32.12 KRW | -103.207% |
| LegoChem Biosciences, Inc. | -2595.00 KRW | 97.485% |
| PharmaResearch Co., Ltd. | 7502.00 KRW | 100.87% |
| SillaJen, Inc. | -179.98 KRW | 63.735% |
| JETEMA, Co., Ltd. | 783.21 KRW | 108.334% |
| OliX Pharmaceuticals,Inc | -1323.81 KRW | 95.07% |
| Genomictree Inc. | -391.00 KRW | 83.307% |
| MedPacto, Inc. | -1664.87 KRW | 96.08% |
| D&D Pharmatech | 409.19 KRW | 115.951% |
| EASY BIO,Inc. | 455.00 KRW | 114.345% |
| GI Innovation, Inc. | -1285.69 KRW | 94.923% |